I agree, Phantom, and to add:
"Canada’s SAP exists so that life-
saving technology not currently available for commercial use in Canada can be provided [when
there are no other commercially available alternatives are suitable]
"Dr. Anita Asgar, Co-Director of the Structural Heart Program at the Institut de Cardiologie de
Montreal (Montreal, Canada), [made the request] to Health Canada to use the DurAVR™ THV in a
patient with a failing valve"
"very high risk of poor hemodynamic performance with a conventional ViV
procedure. "
Technically, chart-wise, we should see this have a rocket put up it.
AVR Price at posting:
$21.66 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
